PROYECTOS CONVOCATORIA PÚBLICA
Proiektua PI16/00002
HVEM / BTLA / CD160 Y PD-L1/PD1 como dianas inmunoterapéuticas en el tratamiento de tumores hematopoyéticos
Finantzatzailea:
INSTITUTO DE SALUD CARLOS III (ISCIII)
date_range
Iraupena 2019(e)ko apirila-(a)k 02-(e)tik 2020(e)ko iraila-(a)k 30-(e)ra izan da
(18 months)
euro
23.740,70 EUR
Nazioarteko-arlokoak.
Ikertzaileak
(5) proiektuarekin lotutako argitalpenak
Erakutsi urterokoaren araberaArtikulua
-
Assesment of Hypoderma infestation in a wild population of Cervus elaphus from mountains Atlantic ecosystems in southwestern Europe (Spain)
2024
Veterinary Research Communications
-
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
2023
Frontiers in Immunology
-
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
2022
Translational Research
-
Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
2022
Frontiers in Immunology
-
Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model
2020
Cancer Immunology, Immunotherapy